Quick Answer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Cash and Equivalents of $213.77 million for fiscal year 2025.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $213.77M | +9.8% |
| 2024 | $194.61M | -29.7% |
| 2023 | $276.77M | +18.3% |
| 2022 | $233.91M | -3.0% |
| 2021 | $241.21M | +5.6% |
| 2020 | $228.42M | -4.0% |
| 2019 | $238.01M | +21.8% |
| 2018 | $195.44M | +19.3% |
| 2017 | $163.79M | +39.2% |
| 2016 | $117.63M | -0.3% |
| 2015 | $117.95M | -26.3% |
| 2014 | $160.02M | +2.6% |
| 2013 | $155.93M | +42.2% |
| 2012 | $109.69M | +59.2% |
| 2011 | $68.91M | -61.5% |
| 2010 | $179.16M | -1.9% |
| 2009 | $182.57M | -25.0% |
| 2008 | $243.59M | +8.0% |
| 2007 | $225.45M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $207.10M | -1.5% | +13.3% |
| June 30, 2025 | $182.82M | +2.0% | -20.3% |
| March 31, 2025 | $229.36M | -29.9% | +17.9% |
| December 31, 2024 | $194.61M | -29.7% | -7.4% |
| September 30, 2024 | $210.17M | +33.7% | +17.3% |
| June 30, 2024 | $179.21M | -10.6% | -45.2% |
| March 31, 2024 | $327.04M | +62.2% | +18.2% |
| December 31, 2023 | $276.77M | +18.3% | +76.1% |
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. showed an increase of +9.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s cash and equivalents has declined by 5.2% (from $225.45 million to $213.77 million).
- The most recent figure is from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: